Shares of Healthcare sector company Eiger BioPharmaceuticals moved -69.3% today, and are now trading at a price of $1.18. The small-cap stock's daily volume was 2,412,969 compared to its average volume of 337,326. The S&P 500 index returned a 0.3% performance.
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. The company is based in Palo Alto and has 54 full time employees. Its market capitalization is $52,007,672.
4 analysts are following Eiger BioPharmaceuticals and have set target prices ranging from $20 to $48 per share. On average, they have given the company a rating of strong buy. At today's prices, EIGR is trading -96.22% away from its average analyst target price of $31.25 per share.
Over the last year, EIGR shares have gone down by -37.2%, which represents a difference of -21.4% when compared to the S&P 500. The stock's 52 week high is $10.02 per share and its 52 week low is $1.18. Eiger BioPharmaceuticals has averaged free cash flows of $-60,478,000.0 over the last four years, with a mean growth rate of -20.5%. It is likely that the stock will keep following its current negative performance trend while the underlying business is experiencing such poor cash flows.
